# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Vernon Bernardino reiterates Edesa Biotech (NASDAQ:EDSA) with a Buy and maintains $21 price ...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrom...
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.69)...
HC Wainwright & Co. analyst Vernon Bernardino reiterates Edesa Biotech (NASDAQ:EDSA) with a Buy and maintains $21 price ...
Shares of ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA P...
HC Wainwright & Co. analyst Vernon Bernardino maintains Edesa Biotech (NASDAQ:EDSA) with a Buy and lowers the price targ...